Open Access Research

BackgroundHepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with poor prognosis due to resistance to conventional chemotherapy and limited efficacy of radiotherapy. There is an urgent need to develop novel biomarkers for early diagnosis, as well as to identify new drug targets for therapeutic interventions.Patients and methods54 paired HCC samples and 21 normal liver tissues were obtained from West China Hospital of Sichuan University. Informed consent was obtained from all the patients or their relatives prior to analysis, and the project was approved by the Institutional Ethics Committee of Sichuan University. Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC)-based proteomics was employed to profile the differentially expressed proteins between a HepG2 human hepatoma cell line and an immortal hepatic cell line L02. Validation of PGAM1 expression was performed by semi-quantitative RT-PCR, immunoblot and immunohistochemistry using clinical samples. shRNA expressing plasmids specifically targeting PGAM1 were designed and constructed by GenePharma Corporation (Shanghai, China), and were utilized to silence expression of PGAM1 in vitro and in vivo. Cell proliferation was measured by a combination of colony formation assay and Ki67 staining. Apoptosis was examined by flow cytometry and TUNEL assay.ResultsA total of 63 dysregulated proteins were identified, including 51 up-regulated proteins, and 12 down-regulated proteins (over 2-fold, p < 0.01). Phosphoglycerate mutase 1 (PGAM1) was found markedly upregulated. Clinico-pathological analysis indicated that overexpression of PGAM1 was associated with 66.7% HCC, and strongly correlated with poor differentiation and decreased survival rates (p < 0.01). shRNAs-mediated repression of PGAM1 expression resulted in significant inhibition in liver cancer cell growth both in vitro and in vivo.ConclusionOur studies suggested that PGAM1 plays an important role in hepatocarcinogenesis, and should be a potential diagnostic biomarker, as well as an attractive therapeutic target for hepatocellular carcinoma.

[1]  Yuquan Wei,et al.  Inhibition of proliferation and induction of apoptosis by abrogation of heat-shock protein (HSP) 70 expression in tumor cells , 1995, Cancer Immunology, Immunotherapy.

[2]  T. Tsuruo,et al.  De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy , 2009, British Journal of Cancer.

[3]  N. Narayanan,et al.  Resveratrol-induced cell growth inhibition and apoptosis is associated with modulation of phosphoglycerate mutase B in human prostate cancer cells: two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and mass spectrometry evaluation. , 2004, Cancer detection and prevention.

[4]  Hong Wang,et al.  Protein profiles associated with survival in lung adenocarcinoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Gillies,et al.  Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? , 2007, Journal of bioenergetics and biomembranes.

[6]  J. Carreras,et al.  Effects of Thyroid Hormone and Hypoxia on 2,3-Bisphosphoglycerate, Bisphosphoglycerate Synthase and Phosphoglycerate Mutase in Rabbit Erythroblasts and Reticulocytes in vivo , 2004, Hormone Research in Paediatrics.

[7]  J. Marrero,et al.  Diagnosis and treatment of hepatocellular carcinoma. , 2008, Gastroenterology.

[8]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[9]  R. Epstein,et al.  Management of advanced hepatocellular carcinoma in the era of targeted therapy , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[10]  J. Sung,et al.  Lentivirus‐mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down‐regulation of stathmin , 2007, Hepatology.

[11]  A. Ortega,et al.  Glucose avidity of carcinomas. , 2009, Cancer letters.

[12]  P. Pedersen,et al.  Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. , 2001, Cancer letters.

[13]  Y. Ishibashi,et al.  Purification and identification of monoubiquitin‐phosphoglycerate mutase B complex from human colorectal cancer tissues , 2001, International journal of cancer.

[14]  K. Krapfenbauer,et al.  Identification of differentially expressed, tumor‐associated proteins in oral squamous cell carcinoma by proteomic analysis , 2006, Electrophoresis.

[15]  Y. Kuramitsu,et al.  Current progress in proteomic study of hepatitis C virus-related human hepatocellular carcinoma , 2005, Expert review of proteomics.

[16]  H. Cortez‐Pinto,et al.  Uncoupling proteins and non-alcoholic fatty liver disease. , 2009, Journal of hepatology.

[17]  E. Newsholme,et al.  Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. , 1990, The Biochemical journal.

[18]  P. Schlag,et al.  Suppression of Tumorigenicity in Breast Cancer Cells by the Microfilament Protein Profilin 1 , 2000, The Journal of experimental medicine.

[19]  M. Long,et al.  Evolution of the phosphoglycerate mutase processed gene in human and chimpanzee revealing the origin of a new primate gene. , 2002, Molecular biology and evolution.

[20]  Krista A. Zanetti,et al.  Identification of metastasis‐related microRNAs in hepatocellular carcinoma , 2008, Hepatology.

[21]  S. Dimauro,et al.  Isolation of a cDNA encoding the B isozyme of human phosphoglycerate mutase (PGAM) and characterization of the PGAM gene family. , 1988, The Journal of biological chemistry.

[22]  N. Iizuka,et al.  Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. , 2008, International journal of oncology.

[23]  J. Kok,et al.  Sphingolipid metabolism enzymes as targets for anticancer therapy. , 2004, Current drug targets.

[24]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[25]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[26]  M. F. White,et al.  The two analogous phosphoglycerate mutases of Escherichia coli , 1999, FEBS letters.

[27]  L. Hwang.  Gene therapy strategies for hepatocellular carcinoma. , 2006, Journal of biomedical science.

[28]  Yuquan Wei,et al.  Mechanism of Cancer Cell Adaptation to Metabolic Stress , 2009, Molecular & Cellular Proteomics.

[29]  Yuquan Wei,et al.  Prognostic evaluation of epidermal fatty acid‐binding protein and calcyphosine, two proteins implicated in endometrial cancer using a proteomic approach , 2008, International journal of cancer.

[30]  Xi Jin,et al.  HDMCP uncouples yeast mitochondrial respiration and alleviates steatosis in L02 and hepG2 cells by decreasing ATP and H2O2 levels: a novel mechanism for NAFLD. , 2009, Journal of hepatology.

[31]  Masakazu Yamamoto,et al.  Sectionectomy Is Suitable for Patients with T2 Hepatocellular Carcinoma according to the Modified International Union against Cancer TNM Classification , 2007, Digestive Surgery.

[32]  Yuquan Wei,et al.  VEGF-Targeted Short Hairpin RNA Inhibits Intraperitoneal Ovarian Cancer Growth in Nude Mice , 2010, Oncology.

[33]  David Beach,et al.  Glycolytic enzymes can modulate cellular life span. , 2005, Cancer research.

[34]  Zhuchu Chen,et al.  Proteome analysis of human lung squamous carcinoma , 2006, Proteomics.

[35]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[36]  G. Semenza,et al.  Oncogenic alterations of metabolism. , 1999, Trends in biochemical sciences.

[37]  P. de Atauri,et al.  Characterization of the first described mutation of human red blood cell phosphoglycerate mutase. , 2005, Biochimica et biophysica acta.

[38]  A. Saghatelian,et al.  Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling , 2005, Nature Biotechnology.

[39]  C. Welter,et al.  Phosphoglycerate Mutase-derived Polypeptide Inhibits Glycolytic Flux and Induces Cell Growth Arrest in Tumor Cell Lines* , 2004, Journal of Biological Chemistry.

[40]  Louise Lantier,et al.  AMPK: Lessons from transgenic and knockout animals. , 2009, Frontiers in bioscience.

[41]  Xin Zhao,et al.  Over-expression of gastrin-releasing peptide in human esophageal squamous cell carcinomas. , 2004, Carcinogenesis.

[42]  Qingling Zhang,et al.  Identification of potential genes/proteins regulated by Tiam1 in colorectal cancer by microarray analysis and proteome analysis , 2008, Cell biology international.

[43]  E. Lamani,et al.  A cofactor‐dependent phosphoglycerate mutase homolog from Bacillus stearothermophilus is actually a broad specificity phosphatase , 2001, Protein science : a publication of the Protein Society.

[44]  R. Moreno-Sánchez,et al.  Experimental validation of metabolic pathway modeling , 2008, The FEBS journal.

[45]  J. Prieto,et al.  New therapies for hepatocellular carcinoma , 2006, Oncogene.

[46]  Yuquan Wei,et al.  Proteomic analysis of cellular protein alterations using a hepatitis B virus‐producing cellular model , 2008, Proteomics.

[47]  S. Kasibhatla,et al.  Why target apoptosis in cancer treatment? , 2003, Molecular cancer therapeutics.

[48]  Jia-wei Jin,et al.  Profilin 1 obtained by proteomic analysis in all‐trans retinoic acid‐treated hepatocarcinoma cell lines is involved in inhibition of cell proliferation and migration , 2006, Proteomics.

[49]  L. Yu,et al.  Mouse phosphoglycerate mutase M and B isozymes: cDNA cloning, enzyme activity assay and mapping. , 2001, Gene.

[50]  P. Fernández,et al.  Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma , 1999, British Journal of Cancer.

[51]  Howard Y. Chang,et al.  Genomewide view of gene silencing by small interfering RNAs , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[53]  Yiguo Jiang,et al.  Silencing of N-Ras gene expression using shRNA decreases transformation efficiency and tumor growth in transformed cells induced by anti-BPDE. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[54]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[55]  Robert A. Harris,et al.  Pyruvate Dehydrogenase Complex Activity Controls Metabolic and Malignant Phenotype in Cancer Cells* , 2008, Journal of Biological Chemistry.

[56]  K. Inoki,et al.  TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival , 2003, Cell.